Bora Keum

Prof. Bora Keum


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Intestinal Research
Verified
Journal Article
Open access
PDF file
SNSoo-young Na
Soo-young Na
CCChang Hwan Choi
Chang Hwan Choi
ESEun Mi Song
Eun Mi Song
KBKi Bae Bang
Ki Bae Bang
SPSang Hyoung Park
Sang Hyoung Park
JKJoo Sung Kim
Joo Sung Kim
Ulcerative colitis (UC), a relapsing-remitting chronic inflammatory bowel disease (IBD), has a variable natural course but potentially severe disease course. Since the development of anti-tumor necrosis factor (TNF) agents has changed the natural disease course of moderate-to-severe UC, therapeutic options for patients who failed conventional treatments are expanding rapidly. IBD clinical trials have demonstrated the potential efficacy and safety of novel biologics such as anti-integrin α4β7 and anti-interleukin-12/23 monoclonal antibodies and small molecules such as a Janus kinase inhibitor. Anti-TNF biosimilars also have been approved and are widely used in IBD patients. Wise drug choices should be made considering evidence-based efficacy and safety. However, the best position of these drugs remains several questions, with limited data from direct comparative trials. In addition, there are still concerns to be elucidated on the effect of therapeutic drug monitoring and combination therapy with immunomodulators. The appropriate treatment regimens in acute severe UC and the risk of perioperative use of biologics are unclear. As novel biologics and small molecules have been approved in Korea, we present the Korean guidelines for medical management of adult outpatients with moderate-to-severe UC and adult hospitalized patients with acute severe UC, focusing on biologics and small molecules.

16 December 2010 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
SPSung Chul Park
Sung Chul Park
BKBora Keum
Bora Keum
YSYeon Seok Seo
Yeon Seok Seo
YKYong Sik Kim
Yong Sik Kim
YJYoon Tae Jeen
Yoon Tae Jeen
HRHo Sang Ryu
Ho Sang Ryu

25 November 2014 in Digestive and Liver Disease
Verified
Journal Article
Closed access
PDF file
IYIn kyung Yoo
In kyung Yoo
JLJong soo Lee
Jong soo Lee
HCHoon Jai Chun
Hoon Jai Chun
YJYoon Tae Jeen
Yoon Tae Jeen
BKBora Keum
Bora Keum
HRHo Sang Ryu
Ho Sang Ryu

3 May 2012 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SUSoon Ho Um
Soon Ho Um
YSYeon Seok Seo
Yeon Seok Seo
JJJin Yong Jung
Jin Yong Jung
JKJin Dong Kim
Jin Dong Kim
HYHyung Joon Yim
Hyung Joon Yim
HRHo Sang Ryu
Ho Sang Ryu

1 November 2012 in Digestive and Liver Disease
Verified
Journal Article
Closed access
HCHyuk Soon Choi
Hyuk Soon Choi
KKKyoung Oh Kim
Kyoung Oh Kim
HCHoon Jai Chun
Hoon Jai Chun
BKBora Keum
Bora Keum
YSYeon Seok Seo
Yeon Seok Seo
HRHo Sang Ryu
Ho Sang Ryu

30 May 2014 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
EKEun-Sun Kim
Eun-Sun Kim
WLWoo Jin Lee
Woo Jin Lee
YJYoon Tae Jeen
Yoon Tae Jeen
HCHyuk Soon Choi
Hyuk Soon Choi
BKBora Keum
Bora Keum
HRHo Sang Ryu
Ho Sang Ryu
Objectives. The superiority of conventional polyethylene glycol (PEG) solution over sodium picosulfate with magnesium citrate (SPMC) for bowel preparation remains controversial. Therefore, this study compared the efficacy, safety, and tolerability of different regimens of SPMC and PEG solution in Koreans, who consume a traditional high-fiber diet. Materials and methods. A total of 200 outpatients undergoing elective colonoscopy were randomized into four groups receiving different bowel-preparation regimens in a prospective study: 4 L PEG in the morning on the day of colonoscopy, two 2 L split doses of PEG, split doses of 2 SPMC sachets, and split doses of 3 SPMC sachets. Bowel cleansing efficacy was assessed based on the Ottawa bowel preparation scale and the Aronchick scale by endoscopists blinded to treatment, and patients filled out a questionnaire to determine satisfaction. Results. There was no difference among groups with respect to bowel cleansing grade (Ottawa scale, p = 0.314). Patients in the SPMC groups were less likely to have abdominal fullness, pain, nausea, or vomiting than patients in the PEG groups (p < 0.05). Patients reported SPMC was more palatable than PEG. There were no significant differences among groups with respect to polyp detection rate. Conclusion. SPMC is as effective as conventional high-volume PEG–electrolyte solution in Korean patients. SPMC groups reported superior palatability and tolerability compared to PEG groups.